Eli Lilly's GLP-1s as healthcare cost reducers
The bull case for Eli Lilly rests on its GLP-1 drugs like Zepbound being framed not just as weight-loss treatments but as broad healthcare cost reducers, which could drive permanent insurance coverage and massive free cash flow growth.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.